<!DOCTYPE html>
<html>
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" name="viewport"/>
<link href="../../../webpages.css" rel="stylesheet"/>
</head>
<body>
<div class="banner">
<div class="banner-content">
<h1>DermpathNet</h1>
</div>
</div>
<nav>
<a href="../../../index.html" target="_blank">
<text type="button">Home</text>
</a>
<a href="../../../browser-page-317.html" target="_blank">
<text type="button">Browse</text>
</a>
<a href="../../../download-page.html" target="_blank">
<text type="button">Downloads</text>
</a>
<a href="../../../contact-us.html" target="_blank">
<text type="button">About</text>
</a>
</nav>
<footer class="site-footer">
<p>@2024 New York University Grossman School of Medicine, Weill Cornell Medicine</p>
<!--<p>Privacy Policy | Terms of Service | Cookie Policy</p>-->
</footer>
<title>Long-Term Outcome of Neoadjuvant Tyrosine Kinase Inhibitors Followed by Complete Surgery in Locally Advanced Dermatofibrosarcoma Protuberans.-DermPath</title>
<div class="content-container"> <div class="figures-container"> <div class="image-side"> <img alt="Long-Term Outcome of Neoadjuvant Tyrosine Kinase Inhibitors Followed by Complete Surgery in Locally Advanced Dermatofibrosarcoma Protuberans." class="clickable-image" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65a0/8124845/f00e044d2d4d/cancers-13-02224-g002.jpg"/> </div> <div class="text-side"> <h1>Long-Term Outcome of Neoadjuvant Tyrosine Kinase Inhibitors Followed by Complete Surgery in Locally Advanced Dermatofibrosarcoma Protuberans.</h1> <p>Treatment of DFSPs with IM leads to a decrease of atypical spindle cells density, induction of hyalinic fibrosis (HES coloration), and enrichment of activated T cells (CD3 and CD8 labelling) original magnification × 10. (A)—Naïve DFSP tumor with atypical spindle cells (HES coloration). (B,C)—Representative CD3 and CD8 staining on DFSP tumor before TKI treatment. (D)—DFSP tumor after TKI therapy showing reduction of spindle cells and fibrosis (HES coloration). (E,F)—Representative CD3 and CD8 staining on DFSP tumor after TKI treatment, showing a moderate tumoral infiltrate of activated T cells.</p> <p>PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/34066400/" target="_blank">34066400</a></p><p>Type: Premalignant/Malignant, Category: Fibrohistiocytic</p>
</div> </div></div></body></html>